专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL256504A Solid pharmaceutical compositions for treating hcv 未知
公开(公告)号：IL256504A
公开(公告)日：2021-09-30
申请号：IL25650417
申请日：2017-12-22
申请人： ABBVIE INC , SEVER NANCY , WESTEDT ULRICH , LANDER UTE , SCHNEIDER KATRIN , STEITZ BENEDIKT , MUELLER THOMAS , REUL REGINA , OBERMILLER CONSTANZE , JAYASANKAR ADIVARAHA , SIMON MICHAEL , GAO YI , HACH HARALD , KYEREMATENG SAMUEL , ASMUS KATHARINA , TONG PING , ZHU DONGHUA , NARIS MARIUS , GARRETT COLLEEN
发明人： SEVER NANCY , WESTEDT ULRICH , LANDER UTE , SCHNEIDER KATRIN , STEITZ BENEDIKT , MUELLER THOMAS , REUL REGINA , OBERMILLER CONSTANZE , JAYASANKAR ADIVARAHA , SIMON MICHAEL , GAO YI , HACH HARALD , KYEREMATENG SAMUEL , ASMUS KATHARINA , TONG PING , ZHU DONGHUA , NARIS MARIUS , GARRETT COLLEEN
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/24 , A61K9/28 , A61K31/4184 , A61K31/454 , A61K31/498 , A61K38/06
摘要： The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

2. 发明专利

IL256945D0 Solid pharmaceutical compositions for treating hcv 未知
公开(公告)号：IL256945D0
公开(公告)日：2018-03-29
申请号：IL25694518
申请日：2018-01-16
申请人： ABBVIE INC , SEVER NANCY , WESTEDT ULRICH , LANDER UTE , SCHNEIDER KATRIN , STEITZ BENEDIKT , MUELLER THOMAS , REUL REGINA , OBERMILLER CONSTANZE , JAYASANKAR ADIVARAHA , SIMON MICHAEL , GAO YI , HACH HARALD , KYEREMATENG SAMUEL , ASMUS KATHARINA , TONG PING , ZHU DONGHUA , NARIS MARIUS , GARRETT COLLEEN
发明人： SEVER NANCY , WESTEDT ULRICH , LANDER UTE , SCHNEIDER KATRIN , STEITZ BENEDIKT , MUELLER THOMAS , REUL REGINA , OBERMILLER CONSTANZE , JAYASANKAR ADIVARAHA , SIMON MICHAEL , GAO YI , HACH HARALD , KYEREMATENG SAMUEL , ASMUS KATHARINA , TONG PING , ZHU DONGHUA , NARIS MARIUS , GARRETT COLLEEN
IPC分类号： A61K20060101
摘要： The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

3. 发明专利

IL256504D0 Solid pharmaceutical compositions for treating hcv 未知
公开(公告)号：IL256504D0
公开(公告)日：2018-02-28
申请号：IL25650417
申请日：2017-12-22
申请人： ABBVIE INC , SEVER NANCY , WESTEDT ULRICH , LANDER UTE , SCHNEIDER KATRIN , STEITZ BENEDIKT , MUELLER THOMAS , REUL REGINA , OBERMILLER CONSTANZE , JAYASANKAR ADIVARAHA , SIMON MICHAEL , GAO YI , HACH HARALD , KYEREMATENG SAMUEL , ASMUS KATHARINA , TONG PING , ZHU DONGHUA , NARIS MARIUS , GARRETT COLLEEN
发明人： SEVER NANCY , WESTEDT ULRICH , LANDER UTE , SCHNEIDER KATRIN , STEITZ BENEDIKT , MUELLER THOMAS , REUL REGINA , OBERMILLER CONSTANZE , JAYASANKAR ADIVARAHA , SIMON MICHAEL , GAO YI , HACH HARALD , KYEREMATENG SAMUEL , ASMUS KATHARINA , TONG PING , ZHU DONGHUA , NARIS MARIUS , GARRETT COLLEEN
IPC分类号： A61K20060101
摘要： The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

4. 发明申请

WO2006087218A1 HERSTELLUNG VON DOSIERUNGSFORMEN AUS WIRKSTOFFHALTIGEN SCHMELZEN 审中-公开
标题翻译：制造活性物质含熔体的剂型的
公开(公告)号：WO2006087218A1
公开(公告)日：2006-08-24
申请号：PCT/EP2006/001475
申请日：2006-02-17
申请人： ABBOTT GMBH & CO. KG , ROSENBERG, Jörg , STEIGER, Norbert , HACH, Harald , BREITENBACH, Jörg
发明人： ROSENBERG, Jörg , STEIGER, Norbert , HACH, Harald , BREITENBACH, Jörg
IPC分类号： A61J3/10
CPC分类号： A61J3/10 , A61J2200/20 , B30B11/16
摘要： Beschrieben wird ein Verfahren zur Herstellung von Dos ierungs formen, bei dem man zwei Trennfolien (7) in einem definierten Bereich aneinander bringt, zwischen die Trennfolien (7) eine wirkstof fhaltige Schmelze einbringt, so dass in wenigstens einer der Trennfolien (7) eine Tasche zur Aufnahme einer Portion der Schmelze ausgebildet wird, und die Trennfolien (7) voneinander trennt, um die Portion zu entformen. Vorzugsweise wird ein Verfahren beschrieben, bei dem man die Trennfolien (7) im Spalt zweier gegenläufig rotierender Formwalzen (2,3) aneinander bringt, die auf ihrer Oberfläche einander gegenüber liegende Vertiefungen (4,5) aufweisen und in die die Trennfolien (7) bei Einbringung der wirkstof f haltigen Schmelze zur Bildung von Taschen gedrückt werden können. Durch die Trennfolien (7) wird ein direkter Kontakt zwischen Schmelze und Walzen (4,5) und damit Adhäsion der Schmelze an der Walze (2,3) vermieden. Elastisch verformbare Trennfolien (7) unterstützen durch ihre Entspannung die Entformung durch ihre Entspannung nach dem Verlassen des Walzenspaltes (2,3) .
摘要翻译：描述用于DOS的制备方法通货膨胀的形状，包括使2层分离膜（7）在限定的区域彼此中，释放片材（7）之间引入fhaltige熔化，使得在（7）中的袋的分离膜中的至少一个的活性化合物适于接收所述熔体的一部分，并彼此分离的膜（7）脱模的部分。优选地，描述了一种方法，其中一个带来两个反向旋转的模制辊（2,3）的夹持分离薄膜（7）彼此连接，其具有在其表面上彼此相对的凹部（4,5），并且其中所述分离的膜（7）可以在引入活性化合物的被按压含有F熔体以形成口袋。由剥离片（7），所述熔体和辊子（4,5），从而在所述辊上的熔体粘附之间的直接接触（2.3）得以避免。可弹性变形的分离膜（7）可以通过松弛离开辊缝（2.3）后通过其松弛脱模支撑。

5. 发明申请

WO2008037809A1 TRANSMUCOSAL ADMINISTRATION OF FIBRATE COMPOUNDS AND DELIVERY SYSTEM THEREFOR 审中-公开
标题翻译：纤维素化合物的转运管理及其输送系统
公开(公告)号：WO2008037809A1
公开(公告)日：2008-04-03
申请号：PCT/EP2007/060347
申请日：2007-09-28
申请人： Abbott GmbH & Co. KG , WESTEDT, Ulrich , SCHNEIDER, Katrin , STEIGER, Norbert , HACH, Harald , RODE, Marc , RIEPEN, Takeo , MAEGERLEIN, Markus , ROSENBERG, Jörg , BREITENBACH, Jörg , MARSH, Kennan
发明人： WESTEDT, Ulrich , SCHNEIDER, Katrin , STEIGER, Norbert , HACH, Harald , RODE, Marc , RIEPEN, Takeo , MAEGERLEIN, Markus , ROSENBERG, Jörg , BREITENBACH, Jörg , MARSH, Kennan
IPC分类号： A61K9/00 , A61K9/70 , A61K31/216
CPC分类号： A61K9/7007 , A61K9/0056 , A61K9/006 , A61K31/216
摘要： The invention provides a method and a delivery system for the administration of a fibrate compound to a subject in need thereof by bringing the delivery system into contact with a mucous membrane of the subject for a time sufficient to deliver a therapeutically effective amount of the fibrate compound. The delivery system is preferably film-shaped and comprises a solid dispersion product wherein the fibrate compound is distributed homogenously in a polymer matrix.
摘要翻译：本发明提供了一种方法和递送系统，用于通过使输送系统与受试者的粘膜接触一段足以递送治疗有效量的贝特类化合物的时间，将需要的对象给予贝特类化合物。递送系统优选是膜状的并且包含固体分散体产物，其中所述贝特类化合物在聚合物基质中均匀分布。

6. 发明申请

WO2007135177A1 PRODUCTION OF ENVELOPED PHARMACEUTICAL DOSAGE FORMS 审中-公开
标题翻译：生产包装药物剂型
公开(公告)号：WO2007135177A1
公开(公告)日：2007-11-29
申请号：PCT/EP2007/055023
申请日：2007-05-23
申请人： ABBOTT GMBH & CO. KG , ROSENBERG, Jörg , HACH, Harald , WESTEDT, Ulrich , KNOBLOCH, Martin , BREITENBACH, Jörg
发明人： ROSENBERG, Jörg , HACH, Harald , WESTEDT, Ulrich , KNOBLOCH, Martin , BREITENBACH, Jörg
IPC分类号： A61K9/20 , A61K9/28 , A61K9/00
CPC分类号： A61K9/2893 , A61K9/1617 , A61K9/1652 , A61K9/2027 , A61K9/2059 , A61K9/284 , A61K9/2866 , A61K9/5026 , A61K9/5047 , A61K9/5089
摘要： A process for at least partially enveloping a pharmaceutical dosage form, in which the dosage form is surrounded by a shrinkable film, and the film is subsequently shrunk is described.
摘要翻译：描述了至少部分包封药物剂型的方法，其中剂型被可收缩膜包围，并且膜随后被收缩。

7. 发明申请

WO2009024535A1 PREPARATION OF COMPOSITIONS WITH ESSENTIALLY NONCRYSTALLINE EMBEDDED MACROLIDE ANTIBIOTICS 审中-公开
标题翻译：具有非天然嵌合抗体的组合物的制备
公开(公告)号：WO2009024535A1
公开(公告)日：2009-02-26
申请号：PCT/EP2008/060706
申请日：2008-08-14
申请人： ABBOTT GMBH & CO. KG , WESTEDT, Ulrich , ROSENBERG, Jörg , KNOBLOCH, Martin , STEIGER, Norbert , HACH, Harald
发明人： WESTEDT, Ulrich , ROSENBERG, Jörg , KNOBLOCH, Martin , STEIGER, Norbert , HACH, Harald
IPC分类号： A61K9/14 , A61K9/16 , A61K31/7048 , A61K31/7052
CPC分类号： A61K9/146 , B29C47/40 , B29C47/6056 , B29C47/64
摘要： A description is given of a process for the preparation of a pharmaceutical composition of a macrolide antibiotic in essentially noncrystalline form, in which the macrolide antibiotic, a water-swellable polymer and a proton donor are blended in an extruder in the presence of water and forced through a die, the ratio by weight of the sum of macrolide antibiotic, water-swellable polymer and proton donor to water being at least 1 :1. The macrolide antibiotic is preferably clarithromycin and the water-swellable polymer is preferably chosen from crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose and crosslinked polyacrylic acid.
摘要翻译：描述了制备基本上非结晶形式的大环内酯类抗生素的药物组合物的方法，其中大环内酯类抗生素，水溶胀性聚合物和质子供体在水和挤出机的存在下在挤出机中共混通过模具，大环内酯类抗生素，水溶胀性聚合物和质子供体与水的总量的重量比至少为1:1。大环内酯类抗生素优选为克拉霉素，水溶胀性聚合物优选选自交联聚乙烯吡咯烷酮，交联羧甲基纤维素钠和交联聚丙烯酸。

8. 发明申请

WO2008055965A1 MELT-PROCESSED IMATINIB DOSAGE FORM 审中-公开
标题翻译： MELT-PROCESSED IMATINIB剂型
公开(公告)号：WO2008055965A1
公开(公告)日：2008-05-15
申请号：PCT/EP2007/062100
申请日：2007-11-08
申请人： ABBOTT GMBH & CO. KG , NOVARTIS AG , BREITENBACH, Jörg , STEIGER, Norbert , HACH, Harald , WESTEDT, Ulrich , KNOBLOCH, Martin , ALTENBURGER, Ralf , LOGGIA, Nicoletta , OGORKA, Jörg
发明人： BREITENBACH, Jörg , STEIGER, Norbert , HACH, Harald , WESTEDT, Ulrich , KNOBLOCH, Martin , ALTENBURGER, Ralf , LOGGIA, Nicoletta , OGORKA, Jörg
IPC分类号： A61K9/20 , A61K31/505
CPC分类号： A61K9/2095 , A61K9/2054
摘要： The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.
摘要翻译：本发明提供了一种剂型，其包含（a）药学有效量的伊马替尼或其盐的熔融加工混合物，（b）至少一种聚合物粘合剂，和（c）至少一种药学上可接受的非离子表面活性剂。本发明提供具有高药物负荷的伊马替尼剂型，其可以以简单和有效的方式制备，以基本上不依赖于pH的方式释放活性成分的伊马替尼剂型和延长释放的伊马替尼剂型。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式